Category Archives: Mood Disorders
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders: Workbook – Oxford Clinical Psychology
http://www.oxfordclinicalpsych.com/view/10.1093/med:psych/9780199772674.001.0001/med-9780199772674 This is a wonderful Unified Protocol to treat most common psychological problems. I think its the Basics. Like Emotion Regulation 101. I will put it in my link. It’s all on the website if you can’t afford the book. Joris
Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial – The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30295-2/fulltext?rss=yes For us, this compares the UBC and MDA groups doing TMS in the Lower Mainland. Looks like both work equally well.
antidepressants for insomnia: the highest evidence thus far.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD010753.pub2/epdf/abstract basically trazodone and doxepin are reasonable alternatives to z drugs
Chief complaint: Homicidal. Assessing violence risk | MDedge Psychiatry
https://www.mdedge.com/psychiatry/article/164162/chief-complaint-homicidal-assessing-violence-risk?oc_slh=a195008f33c4dd0dfa3c16ad9377076b1fbb3e1fab07e5a2e358c01ae920b082&utm_source=News_CPN_eNL_052518_F&utm_medium=email&utm_content=Is your patient likely to become violent?
POEM: Nonopioids equivalent to opioids for severe chronic back, hip, or knee pain with fewer adverse outcomes
Begin forwarded message: From: “Joule – a CMA Company” <cma.ca> Subject: POEM: Nonopioids equivalent to opioids for severe chronic back, hip, or knee pain with fewer adverse outcomes Date: May 15, 2018 at 4:00:03 AM PDT To: “Joris Anton Josef Wiggers” <joriswiggers> Reply-To: cma.ca View the Web version POEMs Research Summaries Your daily update for […]
Read More »
Intranasal Ketamine Succeeds for Resistant Depression
https://www.medscape.com/viewarticle/896510?nlid=122292_329&src=WNL_mdplsnews_180511_mscpedit_psyc&uac=27343DV&spon=12&impID=1630260&faf=1#vp_3 Timeline for S-ketamine intranasal spray, (Janssen), could file for product release by end of the year. Great hype. Low side effects. Good Phase 3 trial data released this month. We are hopeful to use it within 1 year? Game changer? Biggest psychopharma intro in 50 years? Lots of hype…